Analytical Data
-
Gene name
BCAR3
- Application
-
Alternative Names
NSP2; SH2D3B; Novel SH2-containing protein 2; SH2 domain-containing protein 3B
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75815
-
Expression Region
Asp548~Pro818
-
Molecular Weight
61kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCAR3 (Breast Cancer Anti-estrogen Resistance 3) is a protein that has gained significant attention in cancer research, particularly in the context of breast cancer. It is implicated in the development of resistance to anti-estrogen therapies, such as tamoxifen, which are commonly used to treat estrogen receptor-positive breast cancers. Studies have shown that BCAR3 plays a crucial role in signaling pathways that mediate cell proliferation, survival, and migration, contributing to tumor progression and metastasis. Its expression levels have been correlated with poor prognosis and treatment outcomes in breast cancer patients. Researchers have focused on understanding the molecular mechanisms by which BCAR3 influences cellular response to hormonal therapies, leading to insights into its potential as a therapeutic target. This has spurred interest in developing BCAR3-targeted therapies and biomarkers that could predict treatment resistance, ultimately aiming to improve patient outcomes in breast cancer management. Additionally, BCAR3 is involved in various signaling cascades, including those related to PI3K/Akt and MAPK pathways, making it a critical player in the oncogenic processes. Ongoing investigations into the role of BCAR3 in cancer biology may pave the way for novel interventions and personalized treatment strategies, underscoring its significance in oncology research.
